Affordable Access

deepdyve-link
Publisher Website

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors
  • Plotkin, Steven S1
  • Cashman, Neil R2
  • 1 University of British Columbia, Department of Physics and Astronomy and Genome Sciences and Technology Program, Vancouver, BC V6T 1Z1, Canada. Electronic address: [email protected] , (Canada)
  • 2 University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC V6T 2B5, Canada. Electronic address: [email protected] , (Canada)
Type
Published Article
Journal
Neurobiology of Disease
Publisher
Elsevier
Publication Date
Oct 01, 2020
Volume
144
Pages
105010–105010
Identifiers
DOI: 10.1016/j.nbd.2020.105010
PMID: 32682954
Source
Medline
Language
English
License
Unknown

Abstract

Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat Alzheimer's disease. The most extensively developed method to treat the pathologic forms of these proteins is through the administration of exogenous antibodies, or passive immunotherapy. In this review, we discuss the molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating this disease. These challenges include selectively targeting a protein that has misfolded or is pathological rather than the more abundant, healthy protein, designing strategic constructs for immunizing an animal to raise an antibody that has the appropriate conformational selectivity to achieve this end, and clearing the pathological protein species before prion-like cell-to-cell spread of misfolded protein has irreparably damaged neurons, without invoking damaging inflammatory responses in the brain that naturally arise when the innate immune system is clearing foreign agents. The various solutions to these problems in current clinical trials will be discussed. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times